Hans H Shuhaiber

Hans H Shuhaiber, M.D.

Director, Neurocutaneous Program, NF/TSC/VHL

Department: MD-NEUROLOGY-GENERAL SERVICES
Business Phone: (352) 294-5000
Business Email: hshuhaiber@ufl.edu

About Hans H Shuhaiber

The Center for Excellence in Care in Neurofibromatosis at UF HEALTH provides comprehensive and exceptional care for patients and families affected with NF. We are designated clinic as a member of the NFCN ( Neurofibromatosis Clinical network). We also members of the NF Foundation and Network.

Hans H Shuhaiber MD , provides the individualized treatment you need if you’ve been diagnosed with this complex and lifelong condition.

At UF Health, we offer comprehensive treatment and management options for all types of neurofibromatosis, a relatively rare genetic disorder that affects the development of nerve cells and sometimes causes tumors (neurofibromas) to develop in the nervous system.

At UF Health, our patients benefit not just from a single neurofibromatosis specialist, but from the expertise of an entire team of experts. We do not require referrals, and all of our diagnostic, treatment, and supportive care services are available in a single, convenient location. Through our unique approach, each patient has the advantage of receiving several expert opinions from our neurofibromatosis specialist team in one comfortable and familiar place.

Each neurofibromatosis specialist on UF Health multispecialty tumor team has highly focused skills and experience. Consider that:

-Our UF Health neurosurgeons and surgical oncologists address nerve tumors with a high level of precision using advanced, minimally invasive surgical techniques, which also allow them to access difficult-to-reach neurofibromas that have developed near-critical nerve pathways.

-Our UF Health radiation oncologists and medical oncologists incorporate nonsurgical treatment options, such as chemotherapy and radiation therapy, into highly individualized treatment plans, as appropriate.

– Our UF Health supportive care specialists provide a variety of services, including education, counseling, and nutritional support, to help ensure the best possible quality of life for our patients both during and after treatment.

Each neurofibromatosis specialist at UF Health is committed to treating, educating, and supporting individuals who have been diagnosed with this uncommon condition.

If you are a patient or family suffering from Neurofibromatosis. Please contact me directly at hshuhaiber@ufl.edu. I am looking forward to personally helping you with the long-life illness of Neurofibromatosis. We are available for your NF needs 24/7. We accept all insurance plans, and we accept patients as well with no insurance. We are running several investigational clinical trials that would help your underlying NF disease.

Additional Positions:
Director, Neurocutaneous Program
2017 – Current · NF/TSC/VHL
Related Links:

Accomplishments

Director of VHL Clinic – Clinical Care Center (CCC) Member
2024 · VHL Alliance https://www.vhl.org/care-treatment/clinical-care-centers
Director of Tuberous Sclerosis Clinic
2021 · TSC Alliance accredited clinic https://www.tscalliance.org/find-support/tsc-clinics/
Director of NF clinic
2020 · Childhood Tumor Foundation NFCN Clinical Network Membership https://www.ctf.org/understanding-nf/find-a-doctor/#find
Membership
2020 · SNO- SOCIETY OF NEURO-ONCOLOGY

Teaching Profile

Courses Taught
2018
MDC7124 Family Med/Geriatrics
2021
MDC7800 Neurology Clerkship
2023-2024
BMS6020 Clinical Neuroscience
Teaching Philosophy
Education in Neurofibromatosis and lectures for residents, medical students

Board Certifications

  • Adult Neurology
    American Board of Psychiatry & Neurology (ABPN)

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Adrenoleukodystrophy
  • Adult Brain Tumors
  • Chromosome
  • Down syndrome
  • Genetics
  • Hypokalemic periodic paralysis
  • Multiple sclerosis
  • Multiple system atrophy – cerebellar subtype
  • Myasthenia gravis
  • Neurofibromatosis 2
  • Neurofibromatosis-1
  • Tuberous sclerosis

Research Profile

Hans H. Shuhaiber MD, is running industry-sponsored clinical trials to help patients with complex pain issues caused by Plexiform neurofibroma. Please send me an email at hshuhaiber@ufl.edu to evaluate your eligibility for a clinical trial. https://neurology.ufl.edu/divisions/neurofibromatosis-center/neurofibromatosis-clinical-trials/

Areas of Interest
  • Genetic Counseling
  • Genetics of Neurological diseases
  • Neuro-cutaneous Syndromes
  • Population Health
Open Researcher and Contributor ID (ORCID)

0000-0002-1329-3856

Publications

2022
Management of Cavernous Sinus Thrombosis Following Herpes Zoster Ophthalmicus.
Cureus. 14(1) [DOI] 10.7759/cureus.21036. [PMID] 35155004.
2022
Pituitary Apoplexy (PA): Delayed Diagnosis of a Rare Clinical Syndrome in a Patient With a Known Pituitary Adenoma.
Cureus. 14(11) [DOI] 10.7759/cureus.31536. [PMID] 36532899.
2022
Presumptive Diagnosis of Pallister-Hall Syndrome Using Magnetic Resonance Imaging
Cureus. [DOI] 10.7759/cureus.21735. [PMID] 35251807.
2022
Retinal Artery Occlusion in Fibromuscular Dysplasia: A Case Report
Cureus. 14(11) [DOI] 10.7759/cureus.31462. [PMID] 36523738.
2022
Subacute Posterior Inferior Cerebellar Artery Stroke Radiographically Mimicking Lhermitte-Duclos Disease.
Cureus. 14(11) [DOI] 10.7759/cureus.31381. [PMID] 36514563.
2021
Cryptococcosis Presenting as Cerebrovascular Disease.
Cureus. 13(11) [DOI] 10.7759/cureus.19442. [PMID] 34926024.
2021
Moyamoya Disease in a Young Female With Neurofibromatosis Type 1.
Cureus. 13(10) [DOI] 10.7759/cureus.19121. [PMID] 34858759.
2021
Tetrasomy 18p Initially Misdiagnosed as Cerebral Palsy in an Adult Patient.
Cureus. 13(11) [DOI] 10.7759/cureus.20053. [PMID] 34993029.
2012
Analysis of EEG patterns and genotypes in patients with Angelman syndrome.
Epilepsy & behavior : E&B. 23(3):261-5 [DOI] 10.1016/j.yebeh.2011.11.027. [PMID] 22341959.
2006
Fetal deformations: a risk factor for obstetrical brachial plexus palsy?
Pediatric neurology. 35(4):246-9 [PMID] 16996396.
2004
Bilateral decreased oxygenation during focal status epilepticus in a neonate with hemimegalencephaly.
Journal of child neurology. 19(5):394-6 [PMID] 15224715.
2004
Cerebral regional oxygen fluctuations and decline during clinically silent focal electroencephalographic seizures in a neonate.
Journal of child neurology. 19(7):539-40 [PMID] 15526959.
2004
Intrauterine shoulder weakness and obstetric brachial plexus palsy.
Pediatric neurology. 31(3):225-7 [PMID] 15351026.
2004
The role of palmaris muscle tendon in mitral valve annulus reconstruction: a novel technique for mitral valve repair.
The heart surgery forum. 7(5):E519-22 [PMID] 15799937.
2003
Plantaris tendon graft for atrioventricular valve repair: a novel hypothetical technique.
Texas Heart Institute journal. 30(1):42-4; discussion 44 [PMID] 12638670.
1984
Pulmonary function before and sequentially after valve replacement surgery with correlation to preoperative hemodynamic data.
The American review of respiratory disease. 130(3):400-6 [PMID] 6476591.

Grants

Nov 2023 ACTIVE
A CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LERIGLITAZONE IN ADULT MALE SUBJECTS WITH CEREBRAL ADRENOLEUKODYSTROPHY
Role: Principal Investigator
Funding: PREMIER RESEARCH INTERNATIONAL via MINORYX THERAPEUTICS
Feb 2023 ACTIVE
CTOA Shuhaiber – Residuals ?
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Dec 2022 ACTIVE
Qualitative Exit Interviews to Evaluate the Patient Experience in NFX-179-NF1-202
Role: Principal Investigator
Funding: CLINICAL OUTCOMES SOLUTIONS via NFLECTION THERAPEUTICS
Sep 2022 ACTIVE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of REC-994 in the Treatment of Symptomatic Cerebral Cavernous Malformation
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via RECURSION PHARMACEUTICALS
Jul 2022 ACTIVE
A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with Progressive NF2 Mutated Meningiomas
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP via RECURSION PHARMACEUTICALS
Jun 2022 – Mar 2024
A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants with neurofibromatosis type 1
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via *SHANGHAI FOSUN PHARMACEUTICAL IND DEV
Jan 2022 ACTIVE
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects with Cutaneous Neurofibromas
Role: Principal Investigator
Funding: SYMBIO via NFLECTION THERAPEUTICS
Nov 2021 ACTIVE
A Phase III, Multicentre, International Study with a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
Role: Principal Investigator
Funding: ASTRAZENECA PHARM
Nov 2020 ACTIVE
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Role: Principal Investigator
Funding: MEDPACE via SPRINGWORKS THERAPEUTICS
Mar 2020 ACTIVE
UF HEALTH NEUROMEDICINE HOSPITAL
Role: Principal Investigator
Funding: CHILDRENS TUMOR FOU

Education

NEUROLOGY
2013-2015 · New York University Langone School of Medicine
CHILD NEUROLOGY
2010-2013 · Boston University School of Medicine
MEDICAL GENETICS
2008-2010 · Columbia University Medical Center/ New York- Presbyterian Hospital
FAMILY MEDICINE
2005-2008 · West Virginia University School of Medicine
M.D.
1998-2004 · St. George's University School of Medicine (BSc/MD Combined)
BChD Dental Surgery
1995-1998 · University of Leeds School of Dentistry
BSc Pharmacology
1994-1995 · University College London (UCL) School of Life Sciences

Contact Details

Phones:
Business:
(352) 294-5000
Emails:
Business:
hshuhaiber@ufl.edu
Addresses:
Business Mailing:
1505 SW ARCHER RD
GAINESVILLE FL 32608
Business Street:
1505 SW Archer Road
NEUROMEDICINE HOSPITAL
GAINESVILLE FL 32608